Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

56 trials with published results (11%)

Research Maturity

289 completed trials (55% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

33 terminated out of 526 trials

Success Rate

89.8%

+3.2% vs benchmark

Late-Stage Pipeline

16%

83 trials in Phase 3/4

Results Transparency

19%

56 of 289 completed with results

Key Signals

56 with results90% success33 terminated

Data Visualizations

Phase Distribution

328Total
Not Applicable (138)
Early P 1 (7)
P 1 (35)
P 2 (65)
P 3 (46)
P 4 (37)

Trial Status

Completed289
Unknown105
Recruiting46
Terminated33
Not Yet Recruiting19
Active Not Recruiting19

Trial Success Rate

89.8%

Benchmark: 86.5%

Based on 289 completed trials

Clinical Trials (526)

Showing 20 of 20 trials
NCT06321302Phase 2Active Not RecruitingPrimary

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT07592273Phase 2RecruitingPrimary

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

NCT05079399RecruitingPrimary

Biomarker of Diabetic Retinopathy

NCT07588100Phase 1RecruitingPrimary

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

NCT07707856CompletedPrimary

AI Prediction of Treatment Response in DME

NCT07705555Phase 3Not Yet RecruitingPrimary

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

NCT07705607Phase 3Not Yet RecruitingPrimary

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

NCT07705321Active Not Recruiting

Assessment of Retinal Microcirculation in Patients With Type 1 Diabetes Mellitus

NCT04132401CompletedPrimary

AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care

NCT04505566Phase 1CompletedPrimary

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04699864Not ApplicableTerminatedPrimary

Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

NCT06701721Phase 1Recruiting

A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

NCT07255326Not ApplicableCompletedPrimary

Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes

NCT01496625Recruiting

National Eye Institute Biorepository for Retinal Diseases

NCT03076697Completed

Smartphone Screening for Eye Diseases

NCT04661358Phase 3Active Not RecruitingPrimary

Fenofibrate for Prevention of DR Worsening

NCT07318428Not ApplicableCompletedPrimary

AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma

NCT04505618Not ApplicableRecruitingPrimary

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

NCT03752840Not ApplicableRecruiting

Village-Integrated Eye Worker Trial II

NCT04692688Phase 2CompletedPrimary

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Scroll to load more

Research Network

Activity Timeline